Logo image of MDXH

MDXHEALTH (MDXH) Stock Fundamental Analysis

NASDAQ:MDXH - BE0974461940 - Common Stock

3.53 USD
0 (0%)
Last: 9/5/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, MDXH scores 3 out of 10 in our fundamental rating. MDXH was compared to 542 industry peers in the Biotechnology industry. MDXH has a bad profitability rating. Also its financial health evaluation is rather negative. MDXH shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MDXH had negative earnings in the past year.
MDXH had a negative operating cash flow in the past year.
MDXH had negative earnings in each of the past 5 years.
MDXH had a negative operating cash flow in each of the past 5 years.
MDXH Yearly Net Income VS EBIT VS OCF VS FCFMDXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

MDXH's Return On Assets of -33.42% is fine compared to the rest of the industry. MDXH outperforms 63.47% of its industry peers.
The Return On Equity of MDXH (-979.02%) is worse than 81.37% of its industry peers.
Industry RankSector Rank
ROA -33.42%
ROE -979.02%
ROIC N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH Yearly ROA, ROE, ROICMDXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

MDXH's Gross Margin of 61.69% is fine compared to the rest of the industry. MDXH outperforms 78.41% of its industry peers.
In the last couple of years the Gross Margin of MDXH has grown nicely.
The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
MDXH Yearly Profit, Operating, Gross MarginsMDXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDXH has been increased compared to 1 year ago.
The number of shares outstanding for MDXH has been increased compared to 5 years ago.
Compared to 1 year ago, MDXH has a worse debt to assets ratio.
MDXH Yearly Shares OutstandingMDXH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MDXH Yearly Total Debt VS Total AssetsMDXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

MDXH has an Altman-Z score of -2.13. This is a bad value and indicates that MDXH is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.13, MDXH perfoms like the industry average, outperforming 50.92% of the companies in the same industry.
MDXH has a Debt/Equity ratio of 13.81. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of MDXH (13.81) is worse than 83.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 13.81
Debt/FCF N/A
Altman-Z -2.13
ROIC/WACCN/A
WACC9.24%
MDXH Yearly LT Debt VS Equity VS FCFMDXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

MDXH has a Current Ratio of 2.00. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.00, MDXH is not doing good in the industry: 74.72% of the companies in the same industry are doing better.
MDXH has a Quick Ratio of 1.92. This is a normal value and indicates that MDXH is financially healthy and should not expect problems in meeting its short term obligations.
MDXH has a Quick ratio of 1.92. This is in the lower half of the industry: MDXH underperforms 74.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.92
MDXH Yearly Current Assets VS Current LiabilitesMDXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

MDXH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.11%, which is quite impressive.
The Revenue has grown by 28.29% in the past year. This is a very strong growth!
The Revenue has been growing by 50.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.29%
Revenue 1Y (TTM)28.29%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%20.06%

3.2 Future

MDXH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.83% yearly.
Based on estimates for the next years, MDXH will show a very strong growth in Revenue. The Revenue will grow by 25.29% on average per year.
EPS Next Y59.64%
EPS Next 2Y33.16%
EPS Next 3Y26.83%
EPS Next 5YN/A
Revenue Next Year24.3%
Revenue Next 2Y23.25%
Revenue Next 3Y20.54%
Revenue Next 5Y25.29%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MDXH Yearly Revenue VS EstimatesMDXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
MDXH Yearly EPS VS EstimatesMDXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH Price Earnings VS Forward Price EarningsMDXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH Per share dataMDXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as MDXH's earnings are expected to grow with 26.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.16%
EPS Next 3Y26.83%

More info and screens

0

5. Dividend

5.1 Amount

MDXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MDXHEALTH

NASDAQ:MDXH (9/5/2025, 8:00:01 PM)

3.53

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners43.04%
Inst Owner Change0%
Ins Owners8.29%
Ins Owner ChangeN/A
Market Cap96.33M
Analysts86.67
Price Target6.16 (74.5%)
Short Float %0.27%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.39%
Min EPS beat(2)-43.29%
Max EPS beat(2)28.51%
EPS beat(4)1
Avg EPS beat(4)-28.85%
Min EPS beat(4)-55.38%
Max EPS beat(4)28.51%
EPS beat(8)1
Avg EPS beat(8)-62.93%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.39%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)3.83%
Revenue beat(4)3
Avg Revenue beat(4)3.39%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)6.42%
Revenue beat(8)7
Avg Revenue beat(8)4.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.83%
PT rev (3m)4.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.64%
EPS NY rev (1m)-5.57%
EPS NY rev (3m)-2.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.03%
Revenue NY rev (1m)1.1%
Revenue NY rev (3m)1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 16.14
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS5.04
BVpS0.22
TBVpS-2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.42%
ROE -979.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.69%
FCFM N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
F-Score3
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 13.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.37%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.92
Altman-Z -2.13
F-Score3
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)61.59%
Cap/Depr(5y)46.12%
Cap/Sales(3y)6.93%
Cap/Sales(5y)5.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.29%
EPS Next Y59.64%
EPS Next 2Y33.16%
EPS Next 3Y26.83%
EPS Next 5YN/A
Revenue 1Y (TTM)28.29%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%20.06%
Revenue Next Year24.3%
Revenue Next 2Y23.25%
Revenue Next 3Y20.54%
Revenue Next 5Y25.29%
EBIT growth 1Y8.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.65%
EBIT Next 3Y46.4%
EBIT Next 5Y37.88%
FCF growth 1Y21.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.8%
OCF growth 3YN/A
OCF growth 5YN/A